AT
Attovia TherapeuticsAttovia Therapeutics is a clinical-stage biotech developing ATTOBODY-based biotherapeutics for immune-mediated diseases that went public on Nasdaq in August 2026 in an upsized IPO raising ~$332M gross.
8 Pulse stories
TB
Triveni BioTriveni Bio develops genetics-informed antibody and bispecific therapeutics for immunological and inflammatory diseases.
2 Pulse stories
Total Raised
~$588M ($256M private + $332M IPO gross incl. greenshoe, Aug 2026)
$272M
Attovia TherapeuticsTriveni Bio
Last Valuation
$767M at IPO pricing; ~$904M market cap at Nasdaq open (Aug 5, 2026)
Attovia TherapeuticsTriveni Bio
Biotech
Sector
Biotech
2023
Founded
2023
San Carlos, CA
HQ
Waltham, Massachusetts
Public (ATTO)
Status
Private
Attovia Therapeutics investors
venBio PartnersGoldman Sachs AlternativesFrazier Life SciencesDeep Track CapitalIllumina VenturesSanofi VenturesEcoR1 Capital
Triveni Bio investors
Atlas VentureCormorant Asset ManagementAscenta CapitalJanus Henderson InvestorsDeep Track CapitalOrbiMedViking Global InvestorsFidelity Management & Research
Data from Value Add Pulse coverage and company research — see the full threads for Attovia Therapeutics and Triveni Bio.